Molecular and chemical neuropathology

, Volume 21, Issue 2–3, pp 353–368 | Cite as

Altered RNA turnover in carcinogenesis

The diagnostic potential of modified base excretion
  • Christopher C. Marvel
  • John Del Rowe
  • Eric G. Bremer
  • Joseph R. Moskal


Excretion of urinary modified nucleosides is frequently elevated in patients with oncogenic disease. Increases of urinary pseudouridine excretion are now demonstrated in patients with a variety of brain tumors. The potential use of urinary modified base excretion as a cancer marker is discussed and possible sources of the elevated nucleosides are detailed. The specific steps in RNA metabolism that result in increased levels of RNA nucleoside excretion are poorly understood. This knowledge will be necessary to understand the molecular mechanism and the clinical significance of urinary nucleoside excretion in treatment and diagnosis of oncogenic disease.

Index Entries

Urinary nucleosides urinary excretion modified nucleosides tumor markers RNA tRNA pseudouridine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amuro Y., Nakaoka H., Shimomura S., Fujikura M., Yamamoto T., Tamura S. Toshikazu H., and Higashino K. (1988) Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma.Clin. Chim. Acta 178, 151–158.CrossRefGoogle Scholar
  2. Armstrong R. D., Lewis M., Stern S. G., and Cadman E. C. (1986) Acute effect of 5-fluorouracil on cytoplasmic and nuclear dihydrofolate reductase messenger RNA metabolism.J. Biol. Chem. 261, 7366–7371.PubMedGoogle Scholar
  3. Armstrong R. D., Takimoto C. H., and Cadman E. C. (1986b) Fluoropyrimidinemediated changes in small nuclear RNA.J. Biol. Chem. 261, 21–24.PubMedGoogle Scholar
  4. Björk G. R., Ericson J. U., Gustafsson C. E. D., Hagervall T. G., Jonsson Y. H., and Wikstrom P. M. (1987) Transfer RNA modification.Annu. Rev. Biochem. 56, 263–287.CrossRefGoogle Scholar
  5. Borek E., Baliga B. S., Gehrke C. W., Kuo C. W., Belman S., Troll W., and Waalkes T. P. (1977) High turnover rate of transfer RNA in tumor tissue.Cancer Res. 37, 3362–3366.PubMedGoogle Scholar
  6. Cimino F., Russo T., Colonna A., Duilio A., Ammendola F., Costanzo F., Oliva A., Esposito F., and Salvatore F. (1987) Pseudouridine excretion in experimental neoplasms of retroviral origin, inHuman Tumor Markers. de Gruyter, Berlin, pp. 463–474.CrossRefGoogle Scholar
  7. Clark I., MacKenzie J. W., McCoy J. R., and Lin W. (1983) Comparison of urinary modified nucleosides and bases in rats with hepatomas and nephroblastomas, inRecent Results in Cancer Research. Springer-Verlag, Berlin, p. 388–400.Google Scholar
  8. Clark I., Lin W., and Mackenzie J. W. (1990) RNA catabolites in health and disease, inChromatography and Modification of Nucleosides part C: Modified Nucleosides in Cancer and Normal Metabolism Methods and Applications. Amsterdam, Elsevier, pp. C341-C366.CrossRefGoogle Scholar
  9. Cohen M. B., and Glazer R. I. (1985) Cytotoxicity and the inhibition of ribosomal RNA processing in human colon carcinoma cells.Mol. Pharmacol. 27, 308–313.PubMedGoogle Scholar
  10. Drahovsky D., Winkler A., and Skoda J. (1964) Increased urinary pseudouridine excretion in rats following irradiation.Nature 201, 411–412.CrossRefGoogle Scholar
  11. Fischbein A., Sharma O. K., Selikoff I. J., and Borek E. (1983) Urinary excretion of modified nucleosides in patients with malignant mesothelima.Cancer Res. 43, 2971–2974.PubMedGoogle Scholar
  12. Gehrke C. W., Kuo K. C., Waalkes T. P., and Borek E. (1979) Patterns of urinary excretion of modified nucleosides.Cancer Res. 39, 1150–1153.PubMedGoogle Scholar
  13. Gehrke C. W. and Kuo K. C. T. (eds.) (1990a)Chromatography and Modification of Nucleosides part C Modified nucleosides in cancer and normal metabolism methods and applications. J. Chromatog. Elsevier, Amsterdam.Google Scholar
  14. Gehrke C. W. and Kuo K. C. T. (eds.), (1990b)Chromatography and Modification of Nucleosides part D A Comprehensive Database for tRNA and Nucleosides-HPLC, GC, MS, UV, and FT-IR. J. Chromatog. Elsevier, Amsterdam.Google Scholar
  15. Heldman D. A., Grever M. R., Miser J. S., and Trewyn R. W. (1983a) Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.J. Nat. Cancer Ins. 71, 269–273.Google Scholar
  16. Heldman D. A., Grever M. R., Speicher C. E., and Trewyn R. W. (1983b) Urinary excretion of modified nucleosides in chronic myelogenous leukemia.J. Lab. Clin. Med. 101, 783–792.PubMedGoogle Scholar
  17. Heldman D. A., Grever M. R., and Trewyn R. W. (1983c) Differential excretion of modified nucleosides in adult acute leukemia.Blood 61, 291–296.CrossRefGoogle Scholar
  18. Itoh, K., Konno T., Sasaki T., Ishiwata S., Ishida N., and Misugaki M. (1992) Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.Clin. Chim. Acta 206, 181–189.CrossRefGoogle Scholar
  19. Kuchino Y. and Borek E. (1978) Tumor specific phenylalanine tRNA contains two supernumerary methylated bases.Nature 271, 126–129.CrossRefGoogle Scholar
  20. Li Y., Wang S., and Zhong N. (1992) Simultaneous determination of pseudouridine and creatinine in urine of normal children and patients with leukaemia by high performance liquid chromatography.Biomed. Chromatog. 6, 191–193.CrossRefGoogle Scholar
  21. Nass G. (ed.) (1983)Modified Nucleosides and Cancer (Recent Results in Cancer Research), Springer-Verlag, Berlin.Google Scholar
  22. Padgett R. A., Grabowski P. J., Konarska M. M., Seiler S., and Sharp P. A. (1986) Splicing of messenger RNA precursors.Annu. Rev. Biochem. 55, 1119–1150.CrossRefGoogle Scholar
  23. Pergolizzi R. G. and Grunberger D. (1980) The effect of exogenous nutrients on the biosynthesis of Y base in tRNAPhe from Ehrlich ascites carcinoma.Cancer Lett. 8, 329–333.CrossRefGoogle Scholar
  24. Randerath E., Gopalakrishnan A. S., and Randerath K. (1978) Transfer RNA in hepatomas, inMorris Hepatomas, Mechanisms of Regulation, Plenum, New York, pp. 517–564.CrossRefGoogle Scholar
  25. Randerath K., Tseng W.-C., Harris J. S., and Lu L.-J. W. (1983) Specific effects of 5-fluoropyrimidines and 5-azapyrimidines on modification of the 5 position of pyrimidines, in particular the synthesis of 5-methyluracil and 5-methylcytosine in nucleic acids, inRecent Results in Cancer Research Modified Nucleosides and Cancer. Springer-Verlag, Berlin, pp. 283–297.Google Scholar
  26. Rasmuson T., Björk G. R., Hietala S.-0., Stenling, R., and Lungberg B. (1991) Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma.Acta Oncologia 30, 11–15.CrossRefGoogle Scholar
  27. Rasmuson T., Björk G. R., Damber L., Holm S. E., Jacobsson L., Jeppsson A., Stigbrand T., and Westman G. (1983) Tumor markers in bronchogenic carcinoma.Acta Radiolog. Oncology 22, 209–214.CrossRefGoogle Scholar
  28. Rasmuson T. and Björk G. R. (1985) Excretion of pseudouridine in urine as a tumor marker in malignant diseases.Bull. Mol. Biol. Med. 10, 143–154.Google Scholar
  29. Schoch G., Heller-Schoch G., Muller J., Heddrich M., and Gruttner R. (1982) Determination of RNA metabolism as indicator on nutritional status.Klin. Padiatr. 194, 317–319.CrossRefGoogle Scholar
  30. Schoch G., Sander G., Topp H., and Heller-Schoch G. (1990) Modified nucleosides and nucleobases in urine and serum as selective markers for the whole-body turnover of tRNA, rRNA, and mRNA: Future prospects and impact, inChromatography and modification of nucleosides part C Modified nucleosides in cancer and normal metabolism methods and applications, Elsevier, Amsterdam, pp. C389-C442.CrossRefGoogle Scholar
  31. Tamura S., Amuro, Nakano Y. T., Fuji, J., Yamamoto T., Hada T., and Higashino K. (1986a) Urinary excretion of pseudouridine in patients with hepatocellular carcinoma.Cancer 57, 1571–1575.CrossRefGoogle Scholar
  32. Tamura S., Fujii J., Nakano T., Hada T., and Higashino K. (1986b) Urinary pseudouridine as a tumor marker in patients with small cell lung cancer.Clin. Chim. Acta 154, 125–132.CrossRefGoogle Scholar
  33. Trewyn R. W. and Grever M. R. (1986) Urinary nucleotides in leukemia: laboratory and clinical applications.CRC Critical Reviews in Clinical Laboratory Sciences 24, 71–93.CrossRefGoogle Scholar
  34. Trewyn R. W., Glaser R., Kelly D. R., Jackson D. G., Graham W. P., and Speicher C. E. (1982) Elevated nucleoside excretion by patients with nasopharyngeal carcinoma. Preliminary diagnostic/prognostic evaluations.Cancer 49, 2513–2517.CrossRefGoogle Scholar
  35. Vold B. S., Keith Jr. D. E., and Slavik M. (1982) Urine levels of N-[9-(B-D-ribofuranosyl) (purin-6-y)carbamoyl]-L-threanine, N6-(delta2-isopentenyl)adenosine, and 2′-O-methylguanosine as determined by radioimmunoassay for normal subjects and cancer patients.Cancer Res. 42, 5265–5269.PubMedGoogle Scholar
  36. Waalkes T. P., Abeloff M. D. Ettinger D. S., Woo K. B., Gehrke C. W., Kuo K. C., and Borek E. (1982) Biological markers and small cell carcinoma of the lung. A critical evaluation of urinary ribonucleosides.Cancer 50, 2457–2464.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1994

Authors and Affiliations

  • Christopher C. Marvel
    • 1
  • John Del Rowe
    • 2
  • Eric G. Bremer
    • 3
  • Joseph R. Moskal
    • 3
  1. 1.Department of Radiation Oncology, Southern California Cancer CenterUniversity of Southern CaliforniaLos Angeles
  2. 2.Department of Radiation OncologyMontefiore Medical CenterBronx
  3. 3.Chicago Institute for NeuroSurgery and NeuroResearchChicago

Personalised recommendations